ERIS Lifescience

55
Hold
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE406M01024
  • NSEID: ERIS
  • BSEID: 540596
INR
1,529.80
-21.9 (-1.41%)
BSENSE

Dec 08

BSE+NSE Vol: 20.3 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Operating Income
2,893.00
2,009.00
1,685.00
1,347.00
1,211.00
1,074.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
2,893.00
2,009.00
1,685.00
1,347.00
1,211.00
1,074.00
Expenditure (Ex Depriciation)
Stock Adjustments
-35.00
0.00
3.00
0.00
-38.00
21.00
Raw Materials Consumed
749.00
379.00
348.00
259.00
276.00
150.00
Power & Fuel Cost
15.00
12.00
5.00
4.00
3.00
4.00
Employee Cost
505.00
403.00
346.00
250.00
229.00
205.00
Operating Expenses
35.00
23.00
13.00
7.00
7.00
10.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
254.00
180.00
158.00
101.00
108.00
123.00
Cost of Software developments
0.00
0.00
0.00
0.00
0.00
0.00
Miscellaneous Expenses
144.00
138.00
102.00
85.00
91.00
73.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
1,876.00
1,334.00
1,148.00
862.00
781.00
705.00
Operating Profit (PBDIT) excl Other Income
1,017.00
674.00
536.00
485.00
430.00
368.00
Other Income
18.00
23.00
11.00
26.00
8.00
15.00
Operating Profit (PBDIT)
1,035.00
698.00
547.00
511.00
439.00
383.00
Interest
231.00
84.00
26.00
4.00
1.00
2.00
Profit before Depriciation and Tax
804.00
613.00
521.00
506.00
437.00
381.00
Depreciation
315.00
182.00
117.00
64.00
42.00
50.00
Profit Before Taxation & Exceptional Items
488.00
431.00
404.00
442.00
394.00
331.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
488.00
431.00
404.00
442.00
394.00
331.00
Provision for Tax
114.00
34.00
30.00
36.00
39.00
34.00
Profit After Tax
374.00
397.00
374.00
405.00
355.00
296.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
2,540.00
2,155.00
1,873.00
1,550.00
0.00
1,133.00
Profit Available for appropriations
2,892.00
2,547.00
2,255.00
1,956.00
0.00
1,430.00
Appropriations
2,892.00
2,547.00
2,255.00
1,956.00
0.00
1,430.00
Equity Dividend (%)
735.00%
0.00%
735.00%
601.00%
550.00%
287.00%
Earnings Per Share
25.85
28.82
28.10
29.89
26.16
21.61
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 44.02% vs 19.23% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 50.73% vs 25.73% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 172.75% vs 224.06% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is -5.67% vs 6.14% in Mar 2024

Compare Profit and Loss Results of ERIS Lifescience
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
2,893.00
3,012.00
-119.00
-3.95%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
2,893.00
3,012.00
-119.00
-3.95%
Expenditure (Ex Depriciation)
Stock Adjustments
-35.00
-53.00
18.00
33.96%
Raw Materials Consumed
749.00
1,185.00
-436.00
-36.79%
Power & Fuel Cost
15.00
113.00
-98.00
-86.73%
Employee Cost
505.00
651.00
-146.00
-22.43%
Operating Expenses
35.00
170.00
-135.00
-79.41%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
254.00
137.00
117.00
85.40%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
144.00
221.00
-77.00
-34.84%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
1,876.00
2,619.00
-743.00
-28.37%
Operating Profit (PBDIT) excl Other Income
1,017.00
393.00
624.00
158.78%
Other Income
18.00
62.00
-44.00
-70.97%
Operating Profit (PBDIT)
1,035.00
455.00
580.00
127.47%
Interest
231.00
254.00
-23.00
-9.06%
Profit before Depriciation and Tax
804.00
201.00
603.00
300.00%
Depreciation
315.00
217.00
98.00
45.16%
Profit Before Taxation & Exceptional Items
488.00
-16.00
504.00
3,150.00%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
488.00
-16.00
504.00
3,150.00%
Provision for Tax
114.00
41.00
73.00
178.05%
Profit After Tax
374.00
-57.00
431.00
756.14%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
2,540.00
240.00
2,300.00
958.33%
Profit Available for appropriations
2,892.00
193.00
2,699.00
1,398.45%
Appropriations
2,892.00
193.00
2,699.00
1,398.45%
Equity Dividend (%)
735%
0%
735.00
Earnings Per Share
25.85
-3.02
28.87
955.96%
Profit And Loss - Net Sales
Net Sales 2,893.64 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 44.02% vs 19.23% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 1,017.20 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 50.73% vs 25.73% in Mar 2024

Profit And Loss - Interest
Interest 231.29 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 172.75% vs 224.06% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 374.61 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -5.67% vs 6.14% in Mar 2024